Clinical Trial Update: A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study [Phase 2]

View source ↗

Summary

Phase 2 study of TMC125 (rilpivirine) in HIV-1 infected patients; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Type 1

Drugs mentioned

• TMC125 (dapivirine)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: Human Immunodeficiency Virus Type 1 | Phase 2 | Status: COMPLETED | Results posted: 2013-04-09